Compositions and methods to treat muscular & cardiovascular disorders

Details for Australian Patent Application No. 2007334502 (hide)

Owner Novartis AG

Inventors Schnell, Christian; Beuvink, Iwan; Hall, Jonathan; Mueller, Matthias; Weiler, Jan; Schinke-Braun, Martina; Serluca, Fabrizio

Agent Davies Collison Cave

Pub. Number AU-B-2007334502

PCT Pub. Number WO2008/076324

Priority 60/869,937 14.12.06 US

Filing date 13 December 2007

Wipo publication date 26 June 2008

Acceptance publication date 15 December 2011

International Classifications

C07K 7/00 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

18 June 2009 PCT application entered the National Phase

  PCT publication WO2008/076324 Priority application(s): WO2008/076324

15 December 2011 Application Accepted

  Published as AU-B-2007334502

12 April 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007334504-Interferometric method and instrument for measurement and monitoring blood glucose

2007334499-Engineered anti-TSLP antibody